- Stocks
- Pharma & Healthcare
- ORTIN GLOBAL
ORTIN GLOBAL share price
NSE: ORTINGLOBEPharma & HealthcareDrug Manufacturers - Specialty & Generic
ORTIN GLOBAL at a glance
ORTIN GLOBAL (NSE: ORTINGLOBE) closed at ₹13.53 on 21 Oct 2026. With a market capitalisation of ₹11 Cr, it ranks 3851st by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was −42.8% in FY25. Over the past year the share price has risen 16.6%. Its 52-week range is ₹10.66 (28 Oct 2025) to ₹21.30 (9 Jun 2026); the last close is 36.5% below the high. In Q1 FY13, the quarter ended 30 Jun 2012, revenue was ₹13 Cr (−28.5% year on year) and net profit ₹0 Cr (−63.3%), on a consolidated basis. Promoters held 1.23% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹11 CrRank 3851 on NSE
- Price to book
- 4.11×FY25
- ROE
- −42.8%FY25
- ROCE
- −38.3%FY25
- Debt to equity
- 0.13FY25
- Net profit margin
- −247.3%FY25
- Book value / share
- ₹2.43FY25
- 52-week high
- ₹21.309 Jun 2026
- 52-week low
- ₹10.6628 Oct 2025
- 1-year return
- +16.6%
- RSI (14-day)
- 38.8
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −6.04% | −11.5% | −17.7% | −9.2% | +16.6% |
ORTIN GLOBAL quarterly results
| Quarter | Q1 FY12 | Q4 FY12 | Q1 FY13 |
|---|---|---|---|
| Revenue | ₹18 Cr | ₹17 Cr | ₹13 Cr |
| Revenue YoY | — | — | −28.5% |
| Net profit | ₹1 Cr | ₹1 Cr | ₹0 Cr |
| Net profit YoY | — | — | −63.3% |
| Net margin | 6.5% | 8.2% | 3.3% |
| EPS | ₹0.71 | ₹0.84 | ₹0.26 |
ORTIN GLOBAL financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹197 Cr | ₹8 Cr | ₹8 Cr | ₹6 Cr | ₹2 Cr | ₹0 Cr |
| Operating profit | ₹1 Cr | ₹0 Cr | −₹1 Cr | −₹0 Cr | −₹7 Cr | −₹1 Cr |
| Net profit | −₹1 Cr | ₹1 Cr | −₹0 Cr | −₹0 Cr | −₹8 Cr | −₹1 Cr |
| EPS (₹) | −₹0.33 | ₹1.16 | −₹0.49 | −₹0.12 | −₹9.89 | −₹1.04 |
| Cash from operations | ₹6 Cr | ₹18 Cr | ₹2 Cr | −₹0 Cr | −₹5 Cr | −₹0 Cr |
| Total debt | ₹5 Cr | ₹1 Cr | ₹2 Cr | ₹3 Cr | ₹2 Cr | ₹0 Cr |
| Shareholders' equity | ₹24 Cr | ₹11 Cr | ₹11 Cr | ₹11 Cr | ₹3 Cr | ₹2 Cr |
ORTIN GLOBAL shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 1.23% | 1.23% | 1.23% | 1.23% | 1.23% | 1.23% |
| Foreign institutions | 6.53% | 6.53% | 1.68% | 1.68% | 1.68% | 1.80% |
| Non-institutions | 92.24% | 92.24% | 97.09% | 97.09% | 97.09% | 96.96% |
ORTIN GLOBAL vs peers
The listed Pharma & Healthcare companies nearest to ORTIN GLOBAL by market capitalisation.
Ask anything about ORTIN GLOBAL
Pivot answers on the live chart with evidence you can check, and tests strategies against ORTINGLOBE's own history. Try: “Why has ORTINGLOBE moved over the last three months?” · “Backtest a 50-day moving-average crossover on ORTINGLOBE over five years” · “Compare ORTINGLOBE with NORRIS on margins and valuation”
Frequently asked questions about ORTIN GLOBAL
What is the share price of ORTIN GLOBAL today?
ORTIN GLOBAL (NSE: ORTINGLOBE) last closed at ₹13.53 on 21 Oct 2026. Its 52-week high is ₹21.30 and its 52-week low is ₹10.66.
What is the market cap of ORTIN GLOBAL?
ORTIN GLOBAL's market capitalisation is ₹11 Cr (₹11 Cr) at the 22 Oct 2026 close, ranking 3851st among the NSE companies Pivot tracks.
What is the ROE and ROCE of ORTIN GLOBAL?
Return on equity was −42.8% in FY25 and return on capital employed was −38.3% in FY25 (standalone figures).
Is ORTIN GLOBAL a debt-free company?
No. ORTIN GLOBAL's debt-to-equity ratio was 0.13 in FY25, with total debt of ₹0 Cr.
What were ORTIN GLOBAL's latest quarterly results?
For Q1 FY13 (quarter ended 30 Jun 2012), ORTIN GLOBAL reported revenue of ₹13 Cr, −28.5% year on year, and net profit of ₹0 Cr, −63.3% year on year.
How has ORTIN GLOBAL stock performed over the last year?
ORTIN GLOBAL's share price has risen 16.6% over the past year, −9.2% over three months and −17.7% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of ORTIN GLOBAL?
As of 30 Jun 2026: promoters 1.23%, foreign institutions 1.80%, non-institutions 96.96%.
Who are ORTIN GLOBAL's competitors?
The listed Pharma & Healthcare companies closest to ORTIN GLOBAL by market cap are Norris Medicine, Dolphin Medical, Beryl Drugs, Global Longlife, Looks Health and Broach Lifecare.
Is ORTIN GLOBAL a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out ORTIN GLOBAL's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ORTINGLOBE against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 21 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with O · all NSE stocks · this page as text